Cover Image

Therapeutic Inertia in the Management of Moderate-to-Severe Plaque Psoriasis in Adolescents

Saved in:

Bibliographic Details
Main Authors:	Audrey Melin (Author), Jean-François Sei (Author), Florence Corgibet (Author), Cristèle Nicolas (Author), Rémi Maghia (Author), Bruno Halioua (Author), Alain Beauchet (Author), Emmanuel Mahé (Author)
Format:	Book
Published:	Medical Journals Sweden, 2021-06-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Optimal Management of Plaque Psoriasis in Adolescents: Current Perspectives
by: Mahé E
Published: (2020)

Therapeutic Inertia in the Management of Psoriasis: A Quantitative Survey Among Indian Dermatologists and Patients
by: Rajagopalan M, et al.
Published: (2022)

Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
by: Gisondi P, et al.
Published: (2016)

Stimulation of Organizational Inertia: Identification of the Dimensions and Components of Organizational Inertia at Mazandaran University of Medical Sciences, Iran
by: Kosar Momeni Badeleh, et al.
Published: (2020)

Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis
by: Light JG, et al.
Published: (2021)

Potential role of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
by: Ren V, et al.
Published: (2013)

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
by: Sekhon S, et al.
Published: (2017)

Clinical Utility of Deucravacitinib for the Management of Moderate to Severe Plaque Psoriasis
by: Jin JQ, et al.
Published: (2023)

Real‐life self‐assessment of pruritus relief with a combination of calcipotriol/betamethasone dipropionate foam in patients with plaque psoriasis
by: Laurent Misery, et al.
Published: (2022)

Treatment of moderate‐to‐severe plaque psoriasis with tildrakizumab in the real‐life setting
by: Alessio Gambardella, et al.
Published: (2023)

Certolizumab pegol: new opportunities for treatment of moderate to severe plaque psoriasis
by: A. A. Kubanov, et al.
Published: (2019)

Novel topical therapy for mild-to-moderate plaque psoriasis: focus on calcitriol
by: Lutz Kowalzick
Published: (2009)

Dimethyl fumarate titration for the systemic treatment of moderate-to-severe plaque psoriasis
by: Giovanna Malara, et al.
Published: (2021)

Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting
by: Martina Burlando, et al.
Published: (2021)

Management Strategies for Pediatric Moderate-to-Severe Plaque Psoriasis: Spotlight on Biologics
by: Ruggiero A, et al.
Published: (2023)

Adaptive inertia weight particle swarm algorithm
by: Thakorn Chatchaisathaporn
Published: (2013)

Treatment challenges in the management of moderate-to-severe plaque psoriasis – role of secukinumab
by: Malakouti M, et al.
Published: (2016)

Apremilast and NB-UVB combination therapy in moderate-to-severe plaque type psoriasis
by: O. Yu Olisova, et al.
Published: (2020)

Clinical observation of guselkumab in the treatment of 23 cases of moderate to severe plaque psoriasis
by: Liye XIA, et al.
Published: (2024)

Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date
by: Beck KM, et al.
Published: (2018)

Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review
by: Giampiero Girolomoni, et al.
Published: (2023)

Calcipotriol and Betamethasone Dipropionate Cream Based on PAD Technology for the Treatment of Plaque Psoriasis: A Narrative Review
by: Tiago Torres, et al.
Published: (2023)

Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas
by: Cacciapuoti S, et al.
Published: (2023)

Health-related quality of life among patients with moderate-to-severe plaque psoriasis in Taiwan
by: Tsen-Fang Tsai, et al.
Published: (2018)

Use of Methotrexate in the Treatment of Moderate to Severe Plaque Psoriasis in France: A Practice Survey
by: Fougerousse AC, et al.
Published: (2021)

Comparision of the efficacy and safety between Secukinumab and Adalimumab in the treatment of the moderate to severe plaque psoriasis
by: Dandan HU, et al.
Published: (2023)

Disease severity in moderate‐to‐severe plaque psoriasis: Results from the Belgian REDISCOVER study
by: Tom Hillary, et al.
Published: (2024)

Neutrophil/lymphocyte ratio as serum inflammatory biomarker in patients with moderate-to-severe plaque psoriasis
by: Maria E. Agapito-Valgas, et al.
Published: (2023)

Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis
by: Di Lernia V, et al.
Published: (2016)

Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain
by: Johansson E, et al.
Published: (2018)

Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy
by: Giunta A, et al.
Published: (2017)

Lack of progress in physical activity in Australia: decades of national inertia?
by: Adrian Bauman, et al.
Published: (2024)

Influence of Methotrexate on circulatory levels of T lymphocyte-related cytokines in patients with moderate to severe plaque psoriasis
by: Bei-bei SU, et al.
Published: (2020)

Long-term use of adalimumab in the treatment of moderate to severe plaque psoriasis: a review of the literature
by: Angela Y Moore, et al.
Published: (2010)

Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis
by: April W. Armstrong, et al.
Published: (2024)

Efficacy and safety of secukinumab for moderate to severe plaque psoriasis in children: A report of 10 cases
by: FU Tao, et al.
Published: (2024)

Annual biologic treatment cost for new and existing patients with moderate to severe plaque psoriasis in Greece
by: Fragoulakis V, et al.
Published: (2015)

Tildrakizumab: An Evidence-Based Review of Its Use in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis
by: Näslund-Koch C, et al.
Published: (2020)

Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy
by: Roman M, et al.
Published: (2017)

Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: a meta-analysis of randomized clinical trials
by: Yuqian Wang, et al.
Published: (2023)